Persephone Biosciences vs Saluda Medical

Side-by-side comparison of AI visibility scores, market position, and capabilities

Saluda Medical leads in AI visibility (74 vs 34)
Persephone Biosciences logo

Persephone Biosciences

EmergingLife Sciences & BioTech

Microbiome Diagnostics & Oncology Therapeutics

Persephone Biosciences uses gut microbiome profiling and synthetic biology to develop cancer immunotherapy response predictors and novel therapeutics; founded 2017 in San Diego; received BARDA funding for microbiome-based diagnostics;

AI VisibilityBeta
Overall Score
D34
Category Rank
#180 of 198
AI Consensus
80%
Trend
stable
Per Platform
ChatGPT
29
Perplexity
30
Gemini
29

About

Persephone Biosciences is a biotechnology company founded in 2017 by Stephanie Culler and Chris Calvert and based in San Diego, California. The company focuses on decoding the human gut microbiome to develop diagnostics and therapeutics in oncology and neonatal health. Its core thesis is that the composition of a patient's microbiome significantly affects how they respond to cancer immunotherapies such as checkpoint inhibitors — a hypothesis supported by a growing body of peer-reviewed clinical research. Persephone's diagnostic platform aims to predict immunotherapy response from a patient's microbiome signature prior to treatment initiation.

Full profile
Saluda Medical logo

Saluda Medical

LeaderLife Sciences & BioTech

Neuromodulation & Spinal Cord Stimulation

Saluda Medical is the pioneer of closed-loop spinal cord stimulation (SCS); FDA-approved Evoke SCS system with real-time neural feedback; raised $100M in Jan 2025; received FDA clearance for automated EVA programming platform.

AI VisibilityBeta
Overall Score
B74
Category Rank
#10 of 198
AI Consensus
73%
Trend
stable
Per Platform
ChatGPT
72
Perplexity
68
Gemini
80

About

Saluda Medical is a commercial-stage medical device company that has pioneered closed-loop neuromodulation therapy for chronic pain management. Headquartered in Macquarie Park, Australia (with US operations in Marlborough, Massachusetts), Saluda''s flagship product is the Evoke Spinal Cord Stimulation (SCS) System — the world''s first SCS system that senses and measures neural responses to stimulation (evoked compound action potentials, or ECAPs) and automatically adjusts therapy in real time based on each patient''s neurophysiological feedback. This closed-loop approach provides more precise, consistent pain relief compared to conventional open-loop SCS systems.

Full profile

AI Visibility Head-to-Head

34
Overall Score
74
#180
Category Rank
#10
80
AI Consensus
73
stable
Trend
stable
29
ChatGPT
72
30
Perplexity
68
29
Gemini
80
34
Claude
71
36
Grok
71

Key Details

Category
Microbiome Diagnostics & Oncology Therapeutics
Neuromodulation & Spinal Cord Stimulation
Tier
Emerging
Leader
Entity Type
brand
brand

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.